Vet Med - Czech, 2016, 61(3):111-122 | DOI: 10.17221/8762-VETMED

The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a reviewReview

L. Landa1, A. Sulcova2, P. Gbelec3
1 Faculty of Medicine, Masaryk University, Brno, Czech Republic
2 Central European Institute of Technology, Masaryk University, Brno, Czech Republic
3 Veterinary Hospital and Ambulance AA Vet, Prague, Czech Republic

Cannabinoids/medical marijuana and their possible therapeutic use have received increased attention in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veterinary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific literature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary medicine.

Keywords: cannabinoids; medical marijuana; laboratory animals; companion animals; veterinary medicine

Published: March 31, 2016  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Landa L, Sulcova A, Gbelec P. The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. Vet Med-Czech. 2016;61(3):111-122. doi: 10.17221/8762-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, CGTP Collaborators (2013): The concise guide to pharmacology 2013/14: G protein-coupled receptors. British Journal of Pharmacology 170, 1459-1581. Go to original source... Go to PubMed...
    2. Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM (2008): Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. Journal of Natural Products 71, 1427-1430. Go to original source... Go to PubMed...
    3. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertaler L, Mackie K, Rudd MA, Bukoski RD, Kunos G (2004): Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110, 1996-2002. Go to original source... Go to PubMed...
    4. Battista N, Di Tommaso M, Bari M, Maccarrone M (2012): The endocannabinoid system: an overview. Frontiers in Behavioral Neuroscience, 6, DOI: 10.3389/fnbeh.2012.00009. Go to original source... Go to PubMed...
    5. Bisogno T, Melck D, Bobrov MYu, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V (2000): N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. The Biochemical Journal 351, 817-824. Go to original source... Go to PubMed...
    6. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS (2006): Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45, 50-52. Go to original source... Go to PubMed...
    7. Caffarel MM, Andradas C, Perez-Gomez E, Guzman M, Sanchez C (2012): Cannabinoids: A new hope for breast cancer therapy? Cancer Treatment Reviews 38, 911-918. Go to original source... Go to PubMed...
    8. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012): Endocannabinoid signaling and synaptic function. Neuron 76, 70-81. Go to original source... Go to PubMed...
    9. Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A (2010): Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFa release from canine skin mast cells. Veterinary Immunology and Immunopathology 133, 9-15. Go to original source... Go to PubMed...
    10. Cerrato S, Brazis P, della Valle MF, Miolo A, Petrosino S, Di Marzo V, Puigdemont A (2012): Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. The Veterinary Journal 191, 377-382. Go to original source... Go to PubMed...
    11. Chambers AP, Koopmans HS, Pittman QJ, Sharkley KA (2006): AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. British Journal of Pharmacology 147, 109-116. Go to original source... Go to PubMed...
    12. Chien FY, Wang RF, Mittag TW, Podos SM (2003): Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Archives of Ophthalmology 121, 87-90. Go to original source... Go to PubMed...
    13. Contassot E, Wilmotte R, Tenan M, Belkouch MC, Schnuriger V, de Tribolet N, Burkhardt K, Dietrich PY (2004): Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. Journal of Neuropathology and Experimental Neurology 63, 956-963. Go to original source... Go to PubMed...
    14. Croxford JL (2003): Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17, 179-202. Go to original source... Go to PubMed...
    15. Croxford JL, Yamamura T (2005): Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases? Journal of Neuroimmunology 166, 3-18. Go to original source... Go to PubMed...
    16. Darmani NA (2001a): Δ9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24, 198-203. Go to original source... Go to PubMed...
    17. Darmani NA (2001b): Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacology Biochemistry and Behavior 69, 239-249. Go to original source... Go to PubMed...
    18. De Fonseca FR, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M (2005): The endocannabinoid system: physiology and pharmacology. Alcohol and Alcoholism 40, 2-14. Go to original source... Go to PubMed...
    19. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992): Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949. Go to original source... Go to PubMed...
    20. Di Filippo C, Rossi F, Rossi S, D'Amico M (2004): Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/ chemokines and PMN. Journal of Leukocyte Biology 75, 453-459. Go to original source... Go to PubMed...
    21. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI (2006): Neuroprotective and bloodretinal barrier-preserving effects of cannabidiol in experimental diabetes. American Journal of Pathology 168, 235-244. Go to original source... Go to PubMed...
    22. Fattore L, Fadda P, Spano MS, Pistis M, Fratta W (2008): Neurobiological mechanisms of cannabinoid addiction. Molecular and Cellular Endocrinology 286S, S97-S107. Go to original source... Go to PubMed...
    23. Figueiredo AS, Garcia-Crescioni HJ, Bulla SC, Ross MK, McIntosh C, Lunsford K, Bulla C (2013): Suppression of vascular endothelial growth factor expression by cannabinoids in a canine osteosarcoma cell line. Veterinary Medicine: Research and Reports 4, 31-34. Go to original source...
    24. Fisar Z (2009): Phytocannabinoids and endocannabinoids. Current Drug Abuse Reviews 2, 51-75. Go to original source... Go to PubMed...
    25. Fischer KM, Ward DA, Hendrix DVH (2013): Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs. American Journal of Veterinary Research 74, 275-280. Go to original source... Go to PubMed...
    26. Fitzgerald KT, Bronstein AC, Newquist KL (2013): Marijuana poisoning. Topics in Companion Animal Medicine 28, 8-12. Go to original source... Go to PubMed...
    27. Gaffuri AL, Ladarre D, Lenkei Z (2012): Type-1 cannabinoid receptor signaling in neuronal development. Pharmacology 90, 19-39. Go to original source... Go to PubMed...
    28. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995): Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry 232, 54-61. Go to original source... Go to PubMed...
    29. Gaoni Y, Mechoulam R (1964): Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 86, 1646-1647. Go to original source...
    30. Giannini L, Nistri S, Mastroianni R, Cinci L, Vannacci A, Mariottini C, Passani MB, Mannaioni PF, Bani D, Masini E (2008): Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs. Journal of Cellular and Molecular Medicine 12, 2381-2394. Go to original source... Go to PubMed...
    31. Girling SJ, Fraser MA (2011): Cannabis intoxication in three Green iguanas (Iguana iguana). Journal of Small Animal Practice 52, 113-116. Go to original source... Go to PubMed...
    32. Grimaldi C, Pisanti S, Laezza C, Malfitano AM, Santoro A, Vitale M, Caruso MG, Notarnicola M, Iacuzzo I, Portella G, Di Marzo V, Bifulco M (2006): Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research 312, 363-373. Go to original source... Go to PubMed...
    33. Gorji A, Ghadiri MK (2002): History of headache in medieval Persian medicine. Lancet Neurology 1, 510-515. Go to original source... Go to PubMed...
    34. Grotenhermen F (2006): Cannabinoids and the endocannabinoid system. Cannabinoids 1, 10-14.
    35. Grotenhermen F, Muller-Vahl K (2012): The therapeutic potential of cannabis and cannabinoids. Deutsches Arzteblatt International 109, 495-501. Go to original source... Go to PubMed...
    36. Guzman M (2003): Cannabinoids: potential anticancer agents. Nature Reviews Cancer 3, 745-755. Go to original source... Go to PubMed...
    37. Han S, Thatte J, Buzard DJ, Jones RM (2013): Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. Journal of Medical Chemistry 56, 8224-8256. Go to original source... Go to PubMed...
    38. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Frid E (1999): HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proceedings of the National Academy of Sciences of the United States of America 96, 14228-14233. Go to original source... Go to PubMed...
    39. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001): 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences of the United States of America 98, 3662-3665. Go to original source... Go to PubMed...
    40. Hayakawa K, Mishima K, Fujiwara M (2010): Therapeutic potential of non-psychotropic cannabidiol in ischemic stroke. Pharmaceuticals 3, 2197-2212. Go to original source... Go to PubMed...
    41. Heifets BD, Castillo PE (2009): Endocannabinoid signaling and long-term synaptic plasticity. Annual Review of Physiology 71, 283-306. Go to original source... Go to PubMed...
    42. Hildebrandt AL, Kelly-Sullivan DM, Black SC (2003): Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. European Journal of Pharmacology 462, 125-132. Go to original source... Go to PubMed...
    43. Hill AJ, Williams CM, Whalley BJ, Stephens GJ (2012): Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology and Therapeutics 133, 79-97. Go to original source... Go to PubMed...
    44. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009): Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences 30, 515-527. Go to original source... Go to PubMed...
    45. Jan TR, Farraj AK, Harkema JR, Kaminski NE (2003): Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. Toxicology and Applied Pharmacology 188, 24-35. Go to original source... Go to PubMed...
    46. Jones RT (2002): Cardiovascular system effects of marijuana. The Journal of Clinical Pharmacology 42, 58S-63S. Go to original source... Go to PubMed...
    47. Kalant H (2001): Medicinal use of cannabis. Pain Research and Management 6, 80-91. Go to original source... Go to PubMed...
    48. Karst M, Wippermann S, Ahrens J (2010): Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 70, 2409-2438. Go to original source... Go to PubMed...
    49. Keppel Hesselink JM (2012): New targets in pain, nonneuronal cells, and the role of palmitoylethanolamide. The Open Pain Journal 5, 12-23. Go to original source...
    50. Kluger B, Triolo P, Jones W, Jankovic J (2015): The therapeutic potential of cannabinoids for movement disorders. Movement Disorders 30, 313-327. Go to original source... Go to PubMed...
    51. Kucerova J, Tabiova K, Drago F, Micale V (2014): Therapeutic potential of cannabinoids in schizophrenia. Recent Patents on CNS Drug Discovery 9, 13-25. Go to original source... Go to PubMed...
    52. Landa L, Slais K, Machalova A, Sulcova A (2014a): The effect of cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) on behavioural sensitisation to methamphetamine in mice. Veterinarni Medicina 59, 88-94. Go to original source...
    53. Landa L, Slais K, Machalova A, Sulcova A (2014b): Interaction of CB1 receptor agonist arachidonylcyclopropylamide with behavioural sensitisation to morphine in mice. Veterinarni Medicina 59, 307-314. Go to original source...
    54. Lax P, Esquiva G, Altavilla C, Cuenca N (2014): Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration. Experimental Eye Research 120, 175-185. Go to original source... Go to PubMed...
    55. Looney A (2010): Oncology pain in veterinary patients. Topics in Companion Animal Medicine 25, 32-44. Go to original source... Go to PubMed...
    56. LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D (2005): The search for the palmitoylethanolamide receptor. Life Sciences 77, 1685-1698. Go to original source... Go to PubMed...
    57. Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, de Novellis V, Maione S (2013): Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS and Neurological Disorders - Drug Targets 12, 45-54. Go to original source... Go to PubMed...
    58. Lynch ME, Campbell F (2011): Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology 72, 735-744. Go to original source... Go to PubMed...
    59. Lynch ME, Ware MA (2015): Cannabinoids for the treatment of chronic non-cancer pain: An updated systematic review of randomized controlled trials. Journal of Neuroimmune Pharmacology 10, 293-301. Go to original source... Go to PubMed...
    60. Lynch ME, Cesar-Rittenberg P, Hohmann AG (2014): A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management 47, 166-173. Go to original source... Go to PubMed...
    61. Maione S, Costa B, Di Marzo V (2013): Endocannabinoids: A unique opportunity to develop multitarget analgesics. Pain 154, S87-S93. Go to original source... Go to PubMed...
    62. Massi P, Solinas M, Cinquina V, Parolaro D (2013): Cannabidiol as potential anticancer drug. British Journal of Clinical Pharmacology 75, 303-312. Go to original source... Go to PubMed...
    63. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990): Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561- 564. Go to original source... Go to PubMed...
    64. McCarthy LE, Borison HL (1981): Antiemetic activity of N-methyllevonantradol and nabilone in cisplatin-treated cats. Journal of Clinical Pharmacology 21, 30S-37S. Go to original source... Go to PubMed...
    65. Mechoulam R. (2005): Plant cannabinoids: a neglected pharmacological treasure trove. British Journal of Pharmacology 146, 913-915. Go to original source... Go to PubMed...
    66. Mechoulam R, Fride E, Di Marzo V (1998): Endocannabinoids. European Journal of Pharmacology, 359, 1-18. Go to original source... Go to PubMed...
    67. Mechoulam R, Hanus LO, Pertwee R, Howlett AC (2014): Early phytocannabinoid chemistry to endocannabinoids and beyond. Nature Reviews Neuroscience 15, 757-764. Go to original source... Go to PubMed...
    68. Mendizabal VE, Adler-Graschinsky E (2007): Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. British Journal of Pharmacology, 151, 427-440. Go to original source... Go to PubMed...
    69. Meola SD, Tearney CC, Haas SA, Hackett TB, Mazzaferro EM (2012): Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005-2010). Journal of Veterinary Emergency and Critical Care 22, 690-696. Go to original source... Go to PubMed...
    70. Miller LK, Devi LA (2011): The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacological Reviews 63, 461-470. Go to original source... Go to PubMed...
    71. Muccioli GG (2010): Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discovery Today 15, 474-483. Go to original source... Go to PubMed...
    72. Mukhopadhyay P, Batkai S, Rajesh M, Czifra N, HarveyWhite J, Hasko G, Zsengeller Z, Gerard NP, Liaudet L, Kunos G, Pacher P (2007): Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicininduced cardiotoxicity. Journal of the American College of Cardiology 50, 528-536. Go to original source... Go to PubMed...
    73. Munro S, Thomas KL, Abu-Shaar M (1993): Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65. Go to original source... Go to PubMed...
    74. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M (2009): Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry 1, 1333-1349. Go to original source... Go to PubMed...
    75. Nolen RS (2013): With pet owners already using the drug as medicine, veterinarians need to join the debate. Journal of the American Veterinary Medical Association 242, 1604-1609. Go to original source... Go to PubMed...
    76. Pacher P, Batkai S, Kunos G (2006): The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 58, 389-462. Go to original source... Go to PubMed...
    77. Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004): Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 171, 156-161. Go to original source... Go to PubMed...
    78. Pascual D, Goicoechea C, Suardiaz M, Martin MI (2005): A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 118, 23-34. Go to original source... Go to PubMed...
    79. Pate DW, Jarvinen K, Urtti A, Mahadevan V, Jarvinen T (1998): Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sciences 63, 2181-2188. Go to original source... Go to PubMed...
    80. Pertwee RG (1997): Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology and Therapeutics 74, 129-180. Go to original source... Go to PubMed...
    81. Pertwee RG (2005): The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. The AAPS Journal 7, E625-E654. Go to original source... Go to PubMed...
    82. Pertwee RG (2009): Emerging strategies for exploiting cannabinoid receptor agonists as medicines. British Journal of Pharmacology 156, 397-411. Go to original source... Go to PubMed...
    83. Pertwee RG (2014): Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proceedings of the Nutrition Society 73, 96-105. Go to original source... Go to PubMed...
    84. Porcella A, Maxia C, Gessa GL, Pani L (2001): The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. European Journal of Neuroscience 13, 409-412. Go to original source... Go to PubMed...
    85. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002): Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. The Journal of Pharmacology and Experimental Therapeutics 301, 1020-1024. Go to original source... Go to PubMed...
    86. Presley BC, Jansen-Varnum SA, Logan BK (2013): Analysis of synthetic cannabinoids in botanical material: A review of analytical methods and findings. Forensic Science Review 25, 27-46.
    87. Re G, Barbero R, Miolo A, Di Marzo V (2007): Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. The Veterinary Journal 173, 21-30. Go to original source... Go to PubMed...
    88. Robson P (2001): Therapeutic aspects of cannabis and cannabinoids. The British Journal of Psychiatry 178, 107- 115. Go to original source... Go to PubMed...
    89. Rog DJ, Nurmikko TJ, Friede T, Young CA (2005): Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65, 812-819. Go to original source... Go to PubMed...
    90. Ross RA (2003): Anandamide and vanilloid TRPV1 receptors. British Journal of Pharmacology 140, 790-801. Go to original source... Go to PubMed...
    91. Russo EB (2008): Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management 4, 245-259. Go to original source... Go to PubMed...
    92. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H (2008): Cannabinoids for cancer treatment: progress and promise. Cancer Research 15, 339-342. Go to original source... Go to PubMed...
    93. Scarampella F, Abramo F, Noli C (2001): Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Veterinary Dermatology 12, 29-39. Go to original source... Go to PubMed...
    94. Scheen AJ, Paquot N (2009): Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Practice and Research Clinical Endocrinology and Metabolism 23, 103-116. Go to original source... Go to PubMed...
    95. Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E (2014): A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain 18, 999-1012. Go to original source... Go to PubMed...
    96. Slais K, Landa L, Sulcova A (2003): The effects of cannabinoid CB1 receptor antagonist AM 251 on locomotor/ exploratory behaviour and body weight in mice. European Neuropsychopharmacology 13 (Suppl. 4), 417. Go to original source...
    97. Slavic S, Lauer D, Sommerfeld M, Kemnitz UR, Grzesiak A, Trappiel M, Thone-Reineke C, Baulmann J, Paulis L, Kappert K, Kintscher U, Unger T, Kaschina E (2013): Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. Journal of Molecular Medicine 91, 811-823. Go to original source... Go to PubMed...
    98. Song ZH, Slowey CA (2000): Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. Journal of Pharmacology and Experimental Therapeutics 292, 136-139. Go to PubMed...
    99. Stanley CP, Hind WH, O'Sullivan SE (2013): Is the cardiovascular system a therapeutic target for cannabidiol? British Journal of Clinical Pharmacology 75, 313-322. Go to original source... Go to PubMed...
    100. Steffens S, Pacher P (2012): Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. British Journal of Pharmacology 167, 313-323. Go to original source... Go to PubMed...
    101. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Zimmer A, Frossard JL, Mach F (2005): Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782-786. Go to original source... Go to PubMed...
    102. Svizenska I, Dubovy P, Sulcova A (2008): Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - A short review. Pharmacology Biochemistry and Behavior 90, 501-511. Go to original source... Go to PubMed...
    103. Tallett AJ, Blundell JE, Rodgers RJ (2007): Acute anorectic response to cannabinoid receptor antagonist/inverse agonist AM 251 in rat: indirect behavioural mediation. Behavioural Pharmacology 18, 591-600. Go to original source... Go to PubMed...
    104. Unschuld PU (1986): Medicine in China. A History of Pharmaceutics. University of California Press, Berkeley and Los Angele. 167 pp.
    105. Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003): Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. American Journal of Physiology. Gastrointestinal and Liver Physiology 285, 566-576. Go to original source... Go to PubMed...
    106. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA (2005): Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332. Go to original source... Go to PubMed...
    107. Velasco G, Sanchez C, Guzman M (2012): Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer 12, 436-444. Go to original source... Go to PubMed...
    108. Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, Gallily R (2006): Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39, 143-151. Go to original source... Go to PubMed...
    109. Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R (2008): Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 54, 244-249. Go to original source... Go to PubMed...
    110. Xiong W. Cui T, Cheng K, Yang F, Chen SR, Willenbring D, Guan Y, Pan HL, Ren K, Xu Y, Zhang L (2012): Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. Journal of Experimental Medicine 209, 1121-1134. Go to original source... Go to PubMed...
    111. Zuardi AW (2006): History of cannabis as a medicine: a review. The Revista Brasileira de Psiquiatria 28, 153-157. Go to original source... Go to PubMed...
    112. Zubrzycki M, Liebold A, Janecka A, Zubrzycka M (2014): A new face of endocannabinoids in pharmacotherapy.
    113. Part I: Protective role of endocannabinoids in hypertension and myocardial infarction. Journal of Physiology and
    114. Pharmacology 65, 171-181.

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content